CYP3A4 and B-cell chronic lymphocytic leukemia: In a recent retrospective cohort study of 642 patients with CLL receiving ibrutinib therapy in Ontario, Canada, concomitant CYP3A inducers were identified as a significant risk factor for death on multivariable analysis, with CLL being the most common known cause of death [33].